Sinopharm Group (01093) and Cipla have entered into an exclusive licensing agreement for the commercialization of Liposomal Amphotericin B Injection in the United States.

Zhitong Finance APP news, Shiyao Group (01093) announced that the group has entered into an exclusive license agreement with Cipla USA, Inc. (Cipla) for the commercialization of the group's IL-2 liposome injection in the United States.